Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK9 Inhibitors.

Cardiologia Croatica - Croatia
doi 10.15836/ccar2016.330
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medical Publishing, d.o.o.

Related search

Phenome-Wide Association Analysis of LDL-cholesterol Lowering Genetic Variants in PCSK9

BMC Cardiovascular Disorders
Cardiovascular MedicineCardiology
2019English

Beyond Lowering LDL Cholesterol

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2011English

Effects of Currently Prescribed LDL-C-lowering Drugs on PCSK9 and Implications for the Next Generation of LDL-C-lowering Agents

Lipids in Health and Disease
BiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2011English

Potential of PCSK9 as a New Target for the Management of LDL Cholesterol

Research Reports in Clinical Cardiology
2015English

Long-Term Benefits of LDL Cholesterol Lowering in Young Adulthood: A Computer Simulation Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Journal of Atherosclerosis and Thrombosis
BiochemistryInternal MedicineCardiovascular MedicineCardiology
2017English

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

Key Recent Advances in Atherosclerosis Treatment With Modern Lipid-Lowering Drugs: The New Frontier With PCSK9 Inhibitors

European Cardiology Review
Cardiovascular MedicineCardiology
2017English

Cholesterol Lowering for the Prevention of Stroke

Practical Neurology
MedicineNeurology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy